- Home
- AMGN vs UNP Comparison
AMGN vs UNP Comparison
Compare AMGN & UNP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- UNP
- Stock Information
- Founded
- AMGN 1980
- UNP 1862
- Country
- AMGN United States
- UNP United States
- Employees
- AMGN N/A
- UNP N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- UNP Railroads
- Sector
- AMGN Health Care
- UNP Industrials
- Exchange
- AMGN Nasdaq
- UNP Nasdaq
- Market Cap
- AMGN 155.9B
- UNP 130.8B
- IPO Year
- AMGN N/A
- UNP N/A
- Fundamental
- Price
- AMGN $291.10
- UNP $222.18
- Analyst Decision
- AMGN Buy
- UNP Buy
- Analyst Count
- AMGN 21
- UNP 21
- Target Price
- AMGN $323.62
- UNP $254.67
- AVG Volume (30 Days)
- AMGN 2.5M
- UNP 3.1M
- Earning Date
- AMGN 08-05-2025
- UNP 07-24-2025
- Dividend Yield
- AMGN 3.29%
- UNP 2.41%
- EPS Growth
- AMGN 56.16
- UNP 6.03
- EPS
- AMGN 10.94
- UNP 11.10
- Revenue
- AMGN $34,126,000,000.00
- UNP $24,246,000,000.00
- Revenue This Year
- AMGN $7.73
- UNP $2.02
- Revenue Next Year
- AMGN $1.69
- UNP $4.45
- P/E Ratio
- AMGN $26.47
- UNP $20.00
- Revenue Growth
- AMGN 15.56
- UNP 0.63
- 52 Week Low
- AMGN $253.30
- UNP $204.66
- 52 Week High
- AMGN $346.85
- UNP $258.07
- Technical
- Relative Strength Index (RSI)
- AMGN 54.94
- UNP 49.89
- Support Level
- AMGN $286.60
- UNP $219.65
- Resistance Level
- AMGN $299.49
- UNP $226.19
- Average True Range (ATR)
- AMGN 5.47
- UNP 2.83
- MACD
- AMGN 0.21
- UNP -0.15
- Stochastic Oscillator
- AMGN 46.50
- UNP 48.18
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About UNP Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the US, Union Pacific generated $24 billion of revenue in 2024 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.